Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

J Am Heart Assoc 2022;11:e025045 DOI: 10.1161/JAHA.121.025045

This secondary analysis of the CREDENCE trial showed that canagliflozin reduced cardiovascular events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), with a larger absolute benefit for total than first cardiovascular events.